Evidence map›Paper›PMID 41810429›Full record

ArticleJHEP reports : innovation in hepatology2026

Long-term outcomes and temporal trends following liver transplantation for chronic liver disease in the intensive care unit.

Magdalena Meszaros, José Ursic-Bedoya, Audrey Coilly, Claire Francoz, Cristophe Duvoux, Filomena Conti, Francois Faitot, Pauline Houssel-Debry, Jean Hardwigsen, Marie-Noelle Hilleret and 14 more

Registry-linked trialAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06636409 (Long-term Mortality Post Liver Transplantation in the Era of Modern Immunosuppression.), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06636409 active not recruitingnot on this map

Long-term Mortality Post Liver Transplantation in the Era of Modern Immunosuppression.

TypeobservationalSponsorUniversity Hospital, MontpellierRan2023 to 2028Enrolled1,343ConditionsLiver TransplantArmsCollection of medical data
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Magdalena MeszarosLiver Transplant and Hepatogastroenterology Unit, CHU Saint-Eloi, Montpellier University, Montpellier, France.
José Ursic-BedoyaLiver Transplant and Hepatogastroenterology Unit, CHU Saint-Eloi, Montpellier University, Montpellier, France.
Audrey CoillyHepatobiliary Center, AP-HP Paul Brousse Hospital, Villejuif, France.
Claire FrancozHepatology Unit, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, Clichy, France.
Cristophe DuvouxHepatology and Medical Liver Transplant Unit, Henri-Mondor Hospital-APHP, Paris Est University Créteil, France.
Filomena ContiHepatology and Liver Transplant Unit, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Francois FaitotLiver Transplant and Digestive Surgery Unit, Strasbourg University, Strasbourg, France.
Pauline Houssel-DebryLiver Department, Rennes University Hospital and Rennes University, UMR 1317 NuMeCan Institute and REnnes LIvEr Failure Group (RELIEF), France.
Jean HardwigsenHepatogastroenterology Unit, CHU Timone, Marseille, France.
Marie-Noelle HilleretUniversité Grenoble Alpes, Service Hépatogastroenterologie CHUGrenoble Alpes, Inserm U 1209, CNRS UMR 5309, Team Cell Dynamics, Immunity, Metabolism & Cancer, IAB 38000 Grenoble, France.
Claire VanlemmensHepatology Unit, CHRU Jean Minjoz Franche Comté University, Besançon, France.
Laure ElkriefHepatogastroenterology Unit, CHU Tours, Tours, France.
Nassim KamarDepartment of Nephrology and Organ Transplantation, Axe TImE, Toulouse Rangueil University Hospital, INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), University Paul Sabatier, Toulouse, France.
Rodolphe AntyHepatogastroenterology Unit, Nice University, France.
Armand AbergelHepatogastroenterology Unit, CHU Estaing Clermont-Ferrand, Clermont-Ferrand, France.
Claire PerignonDepartment of Hepato-Gastroenterology, CHU Côte de Nacre, Caen, France.
Laurence ChicheHepatogastroenterology Unit, Haut Leveque Hospital, CHU Bordeaux, Bordeaux, France.
Maryline Debette-GratienHepatogastroenterology Unit, CHU Limoges, Limoges, France.
Teresa AntoniniHepatology Unit, HCL, Hôpital de la Croix-Rousse, Lyon, France.
Corinne AntoineDirection Générale Médicale et Scientifique, Agence de la Biomédecine, Saint Denis, France.
Sebastien DharancyHepatology Unit, CHRU Lille, Claude Huriez Hospital, Lille, France.
Jérome DumortierLiver Transplant Unit, Digestive Diseases Federation, Edouard Herriot Hospital, Hospices Civils de Lyon Université, Lyon, France.
Georges Philippe PageauxLiver Transplant and Hepatogastroenterology Unit, CHU Saint-Eloi, Montpellier University, Montpellier, France.
Florent ArtruLiver Department, Rennes University Hospital and Rennes University, UMR 1317 NuMeCan Institute and REnnes LIvEr Failure Group (RELIEF), France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Liver transplantation (LT) remains the definitive treatment for patients with end-stage chronic liver disease (CLD). However, those transplanted while in the intensive care unit (ICU) represent a high-risk population. Large-scale data on long-term prognosis in this group are limited. We aimed to assess long-term outcomes in patients with CLD undergoing LT from the ICU and to compare outcomes over time. Methods: This retrospective cohort study used the French national transplant registry (CRISTAL). Adults with CLD who underwent LT from the ICU between 2008 and 2018 were included. Organ failures were defined according to EASL CLIF-OF criteria. Five-year survival and associated risk factors were analyzed and compared across four time periods (2008-2010, 2011-2013, 2014-2016, 2017-2018). Results: Among 13,372 LTs performed in France during the study period, 9,686 were for CLD, of which 1,287 (13.2%) patients were in the ICU at the time of LT. Alcohol-related liver disease (50%) and viral hepatitis (16.1%) were the leading etiologies. Five-year survival was significantly lower in ICU patients compared with non-ICU patients (69.2% Conclusion: Patients transplanted from the ICU have significantly lower long-term survival, primarily due to elevated early post-transplant mortality, with no observed improvement over time. Careful candidate evaluation and donor selection remain critical to improving outcomes in this high-risk population.ClinicalTrials.gov number NCT06636409. Impact and implications: This large national cohort study provides a comprehensive evaluation of long-term outcomes in critically ill patients with cirrhosis undergoing liver transplantation while in the intensive care unit. Despite advances in transplant care over the past decade, we observed a persistent survival gap in this high-risk population, primarily driven by increased mortality within the first year after transplantation. Age, the need for mechanical ventilation, and donor-related factors were independently associated with this excess risk. We also found no significant improvement in outcomes over time. These results underscore the continued need for refined candidate selection and donor allocation strategies, taking into account age, pre-transplant clinical stability, and graft quality to optimize post-transplant survival.

Indexed as

intensive care unitliver transplantationlong-term mortality

Identifiers

PMID41810429
PMCPMC12969417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.